Literature DB >> 12686095

The influenza vaccine licensing process.

J M Wood1, R A Levandowski.   

Abstract

Influenza vaccines are unique because they require a licensing process which includes a procedure for rapid annual updates to vaccine strains. The licensing procedures in the European Union and the USA are described as examples. In the event of an influenza pandemic, vaccines will be required urgently and licensing process should reflect such needs.

Mesh：

Substances：

Year:  2003        PMID： 12686095     DOI： 10.1016/s0264-410x(03)00073-2

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  20 in total

1.  The phage therapy paradigm: prêt-à-porter or sur-mesure?

Authors:  Jean-Paul Pirnay; Daniel De Vos; Gilbert Verbeken; Maia Merabishvili; Nina Chanishvili; Mario Vaneechoutte; Martin Zizi; Geert Laire; Rob Lavigne; Isabelle Huys; Guy Van den Mooter; Angus Buckling; Laurent Debarbieux; Flavie Pouillot; Joana Azeredo; Elisabeth Kutter; Alain Dublanchet; Andrzej Górski; Revaz Adamia
Journal:  Pharm Res       Date:  2010-11-10       Impact factor: 4.200

Review 2.  Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review.

Authors:  Sheena G Sullivan; Shuo Feng; Benjamin J Cowling
Journal:  Expert Rev Vaccines       Date:  2014-10-28       Impact factor: 5.217

Review 3.  The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines.

Authors:  Pier Luigi Lopalco; Frank DeStefano
Journal:  Vaccine       Date:  2014-11-04       Impact factor: 3.641

Review 4.  [Guillain-Barré syndrome after exposure to influenza].

Authors:  H-P Hartung; B Keller-Stanislawski; R A Hughes; H C Lehmann
Journal:  Nervenarzt       Date:  2012-06       Impact factor: 1.214

5.  Impact of Adjuvants on the Immunogenicity and Efficacy of Split-Virion H7N9 Vaccine in Ferrets.

Authors:  Sook-San Wong; Bryan Kaplan; Mark Zanin; Jennifer Debeauchamp; Lisa Kercher; Jeri-Carol Crumpton; Patrick Seiler; Yilun Sun; Li Tang; Scott Krauss; Robert Webster; Richard J Webby
Journal:  J Infect Dis       Date:  2015-02-23       Impact factor: 5.226

6.  Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model.

Authors:  Laurent Coudeville; Fabrice Bailleux; Benjamin Riche; Françoise Megas; Philippe Andre; René Ecochard
Journal:  BMC Med Res Methodol       Date:  2010-03-08       Impact factor: 4.615

Review 7.  Quantitative review of antibody response to inactivated seasonal influenza vaccines.

Authors:  Jessica C Seidman; Stephanie A Richard; Cécile Viboud; Mark A Miller
Journal:  Influenza Other Respir Viruses       Date:  2011-06-13       Impact factor: 4.380

Review 8.  Current evidence on intradermal influenza vaccines administered by Soluvia™ licensed micro injection system.

Authors:  Giancarlo Icardi; Andrea Orsi; Antonella Ceravolo; Filippo Ansaldi
Journal:  Hum Vaccin Immunother       Date:  2012-01-01       Impact factor: 3.452

9.  Protection against H5N1 Influenza Virus Induced by Matrix-M Adjuvanted Seasonal Virosomal Vaccine in Mice Requires Both Antibodies and T Cells.

Authors:  Freek Cox; Matthijs Baart; Jeroen Huizingh; Jeroen Tolboom; Liesbeth Dekking; Jaap Goudsmit; Eirikur Saeland; Katarina Radošević
Journal:  PLoS One       Date:  2015-12-22       Impact factor: 3.240

10.  Progress in the development of a cervical cancer vaccine.

Authors:  Ursula Winters; Richard Roden; Henry Kitchener; Peter Stern
Journal:  Ther Clin Risk Manag       Date:  2006-09       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.